SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ma-Weaver Jacob

(Last) (First) (Middle)
2261 MARKET STREET
#4307

(Street)
SAN FRANCISCO CA 94114

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARCA biopharma, Inc. [ ABIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
Officer (give title below) X Other (specify below)
See footnote 1
3. Date of Earliest Transaction (Month/Day/Year)
08/29/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy)(1) $1.64 08/29/2024 J(2) 6,000 (2) 01/30/2034 Common stock $13,853.4(3) (2) 0 D
Stock option (right to buy) $2.32 08/29/2024 J(2) 6,000 (2) 12/15/2032 Common stock $9,773.4(3) (2) 0 D
Stock option (right to buy) $2.27 08/29/2024 J(2) 12,000 (2) 06/15/2032 Common stock $20,146.8(3) (2) 0 D
Explanation of Responses:
1. This Form 4 is filed by Jacob Ma-Weaver. Mr. Ma-Weaver, Funicular Funds, LP, and Cable Car Capital LLC may have been deemed to be members of a Section 13(d) group that may have been deemed to collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Following the closing of the Issuer's business combination on August 29, 2024, the Reporting Person is no longer a Director of the Issuer and the group no longer holds more than 10% of its outstanding shares of Common Stock.
2. Pursuant to the terms of the Issuer's business combination agreement, all outstanding Issuer incentive options were canceled, and the holders thereof received an amount in cash equal to the product obtained by multiplying (A) the excess of approximately $3.9489 over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B) the number of shares of the Parent Common Stock underlying such Parent Option.
3. The Reporting Person assigned the proceeds of the option cash-out transactions to Funicular Funds, LP.
Jacob Ma-Weaver 08/30/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ARCA Biopharma (NASDAQ:ABIO)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024 ARCA Biopharma 차트를 더 보려면 여기를 클릭.
ARCA Biopharma (NASDAQ:ABIO)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024 ARCA Biopharma 차트를 더 보려면 여기를 클릭.